Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 25;11:1556. doi: 10.1038/s41467-020-15318-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a, b Germline DNA from healthy volunteers and cancer patients, part of a Pharmacogenetics database with germline DNA derived from blood and with clinical follow-up data available, were sequenced with ddPCR using MET N375N (WT) and N375S-specific probes to determine the distribution and frequency of MET (N375S) genotype in Asian population. Graph (a) and table (b) showing the percentage and number of N375S + cases (heterozygous or homozygous) among healthy volunteers and cancer patients. c–j Relapse-free survival (RFS) of patients with locally advanced diseases who had undergone concurrent chemoradiotherapy or surgery were analyzed with Kaplan–Meier method and log-rank test. RFS (measured from time of treatment/surgery to relapse) for head and neck squamous cell carcinoma (c), lung squamous cell carcinoma (d), lung adenocarcinoma (e), nasopharyngeal carcinoma (f), hepatocellular carcinoma (g), colorectal carcinoma (h), gastric carcinoma (i), and breast carcinoma (j). Subjects who have not reached study-defined endpoint were censored (tick marks) from the analysis (Data cutoff point: January 2018).